Moderna Inc (MRNA)
$122.50
0.00 (0.00%)
MRNA Stock Quote Delayed 30 Minutes
Why Novavax Stock is Still a Strong Buy Even After an 800% Move
While NVAX stock could race higher on news in coming days of its clinical trials results, play this one safe with a trailing stop loss to safeguard any wins you have to date.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
46.92B
PE Ratio
-7.82
EPS
-15.66
Volume (Avg. Vol.)
5,002
Day's Range
-
52-Week Range
$62.55 - $170.47
Dividend & Yield
N/A (N/A)
MRNA Stock Predictions, Articles, and Moderna Inc News
Quick Income from a Put Write on Johnson & Johnson
Earnings season is upon us, and Johnson & Johnson (NYSE:JNJ) will kick off second-quarter reporting for the big pharmaceutical stocks on July 16.
Why Investors Should Take Another Look at Moderna’s Many Advantages
After a solid run since starting at the sub-$20 levels at the start of the year, Moderna (NASDAQ:MRNA) continues to attract plenty of buying and…
Moderna Stock Has a Bright Future After the Coronavirus
Moderna is an underdog in the race to develop a coronavirus vaccine, but MRNA stock could benefit from its novel drug discovery technology.
4 Top Stock Trades for Monday: NIO, DOCU, JPM, MRNA
Nio, JPMorgan, Moderna and DocuSign were our top stock trades from Thursday. Let's look at the charts ahead of next week.
Be Careful with Novavax and the Recent Surge in NVAX Stock
Covid-19 vaccine stocks are on fire, but many of them appear to be out over their skis, including the group's hottest name, NVAX stock.
Enough Already! Ditch Moderna Stock
Whether you bought MRNA stock for the CMV or the coronavirus catalyst, it’s clearly time to sell. With shares appearing to be topping out, cashing out today could be the best call.
Moderna May Not Be What Speculators Thought
With demand sky-high for a coronavirus vaccine, it was only natural that MRNA stock jumped higher on Moderna’s encouraging early stage clinical trial results. However, its questionable practices are now coming into closer view.
Moderna Is Still Worth Investing In Before a Vaccine Is Found
Positive results and a key supply agreement for Moderna highlight the bull case for MRNA stock as a promising coronavirus play.
Why Moderna Stock Is Still Only Good for Speculators
Moderna has become the stock market's great hope for a Covid-19 vaccine, but there are dozens of other candidates.
Why Moderna Stock Looks Quite Risky
Data from the Phase 1 trial of Moderna's coronavirus vaccine was mixed, making MRNA stock risky at its current levels.
The Rewards Outweigh the Risks for Moderna Stock
MRNA stock is a big bet right now, but it also reaps huge rewards if Moderna’s promising trials hold up to further testing.
4 Top Stock Trades for Thursday: LOW, TGT, MRNA, MCK
Target, Lowe's, McKesson and Moderna were our top stock trades for Thursday. That said, here's what the charts look like now.
Does Moderna Stock’s Rally Hold Up Under the Microscope?
MRNA stock continues to reach new highs, leaving investors wondering if Moderna's rally is sustainable over the long term.
